[{"orgOrder":0,"company":"City of Hope","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"Baffr Car-T Cell","moa":"BAFF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Baffr Car-T Cell","moa":"BAFF receptor","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"CLD-101","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intracerebral Injection","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"GeoVax Labs","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Helocyte","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Licensing Agreement","leadProduct":"Triplex","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Helocyte","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Helocyte"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"COH04S1","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"City of Hope \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"City of Hope","sponsor":"Imugene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CF33-hNIS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Lixte Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"LB-100","moa":"||Serine\/threonine protein phosphatase 2A, catalytic subunit, beta isoform | Serine\/threonine protein phosphatase 2A, catalytic subunit, alpha isoform | Serine\/threonine-protein phosphatase 5","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Sotorasib","moa":"GTPase KRas","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Plant Extract\/Herbal","year":"2021","type":"Inapplicable","leadProduct":"White Button Mushroom Extract","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||T cell surface glycoprotein CD3 | B-lymphocyte antigen CD20","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Scopus Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"City of Hope \/ Scopus Biopharma","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Scopus Biopharma"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Teclistamab","moa":"Tumor necrosis factor receptor superfamily member 17 | T cell surface glycoprotein CD3","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"Race Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Bisantrene","moa":"DNA | Alpha-ketoglutarate-dependent dioxygenase FTO","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Race Oncology","highestDevelopmentStatusID":"9","companyTruncated":"City of Hope \/ Race Oncology"},{"orgOrder":0,"company":"City of Hope","sponsor":"National Cancer Institute | Biopharmaceutical Research Company","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"BRC-001","moa":"CB1\/2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ National Cancer Institute | Biopharmaceutical Research Company","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ National Cancer Institute | Biopharmaceutical Research Company"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"Cannabinoid CB1 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"8","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Genentech | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Genentech | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Genentech | National Cancer Institute"},{"orgOrder":0,"company":"City of Hope","sponsor":"Mustang Bio","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"MB-101","moa":"Interleukin 13 receptor alpha-2 (IL13RA2)","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"CytoImmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"||PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"National Cancer Institute | Imugene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"CF33-hNIS-antiPDL1","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ National Cancer Institute | Imugene","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ National Cancer Institute | Imugene"},{"orgOrder":0,"company":"City of Hope","sponsor":"Chimeric","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Chimeric","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Chimeric"},{"orgOrder":0,"company":"City of Hope","sponsor":"National Cancer Institute | CytoImmune Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"COH06","moa":"Cytomegalovirus","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ National Cancer Institute | CytoImmune Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ National Cancer Institute | CytoImmune Therapeutics"},{"orgOrder":0,"company":"City of Hope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Oncology","graph2":"Phase I","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"City of Hope \/ Inapplicable"},{"orgOrder":0,"company":"City of Hope","sponsor":"CytoImmune Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"CYTO NK-203","moa":"IL-15\/PSCA","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ City of Hope"},{"orgOrder":0,"company":"City of Hope","sponsor":"Calidi Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Microorganism","year":"2021","type":"Collaboration","leadProduct":"Allogeneic Neural Stem Cell","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Calidi Biotherapeutics","highestDevelopmentStatusID":"5","companyTruncated":"City of Hope \/ Calidi Biotherapeutics"},{"orgOrder":0,"company":"City of Hope","sponsor":"Griffith University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"ZPAMt","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ Griffith University","highestDevelopmentStatusID":"4","companyTruncated":"City of Hope \/ Griffith University"},{"orgOrder":0,"company":"City of Hope","sponsor":"Ostentus Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"City of Hope","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"City of Hope \/ City of Hope","highestDevelopmentStatusID":"4","companyTruncated":"City of Hope \/ City of Hope"}]
Find Clinical Drug Pipeline Developments & Deals by City of Hope
Details :
NeuroNova (CLD-101) is a novel stem-cell based platform designed to deliver oncolytic viruses to tumors. It is beinf evaluated for the treatment of newly diagnosed high grade glioma.
Details :
The vaccine uses patient-specific biologic components called tumor neoantigens that can help the body mount an immune response to a particular tumor type to treat lymphoplasmacytic lymphoma.
Details :
Under the agreement, Helocyte gains patent rights to use CMV-MVA Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-HIV CAR T Cells for the treatment of adults living with HIV.
Details :
Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Details :
CLD-101 platform, which includes NSC.CRAd-S-pk7, is an allogeneic, “off-the-shelf” therapy comprised of an immortalized NSC line loaded with an engineered oncolytic adenovirus.
Details :
A COVID-19 investigational vaccine COH04S1, elicited neutralizing antibodies against the virus’ spike protein also, produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in Phase 1 clinical tria...
Details :
MB-101, an IL13Rα2-targeted CAR T cell therapy demonstrate durable complete responses in GBM based on a 54-patient Phase 1 trial, as an optimized CAR T product incorporating enhancements in CAR design and T cell engineering to improve antitumor potency ...
Details :
CYTO-102 to be an off-the-shelf cell therapy that can directly kill cancer cells, broadly stimulate the body’s own endogenous immune system, and enhance tumor killing through generation of a highly effective immune response ultimately leading to improv...
Reset All
